20 results
8-K
EX-99.1
RVNC
Revance Therapeutics Inc
9 Nov 21
Provides Corporate Update
4:14pm
. As President, Sjuts will oversee all company operations excluding regulatory, technical operations and general and administrative functions. Sjuts
8-K
RVNC
Revance Therapeutics Inc
9 Nov 21
Provides Corporate Update
4:14pm
, the Chief Executive Officer and principal executive officer of the Company. As President, Mr. Sjuts will oversee all Company operations excluding regulatory
PRE 14A
ypmhx1hhs
12 Mar 21
Preliminary proxy
4:13pm
424B3
v44ekfko93
24 Jun 20
Prospectus supplement
5:18pm
S-4/A
wvk8shhb16sgtahup82c
23 Jun 20
Registration of securities issued in business combination transactions (amended)
6:09am
S-4
0lj60votyfup
9 Jun 20
Registration of securities issued in business combination transactions
9:48pm
8-K
EX-99.1
7no0rmpc7ze9adp
8 May 19
Revance Reports First Quarter 2019 Financial Results and Provides Corporate Update
4:08pm
8-K
pk3hiy7s h37k3j3w
4 Dec 18
Entry into a Material Definitive Agreement
8:14am
- Prev
- 1
- Next